The medicinal chemistry for drug discovery market offers a range of processes, including target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. These stages guide the drug development journey from target identification to final candidate validation. In terms of design, various methodologies are employed, such as fragment-based variation, structure-based drug design, diversity oriented synthesis, chemogenomics, and natural products, among others. These diverse approaches empower researchers to design and develop innovative pharmaceuticals, catering to a broad spectrum of therapeutic needs.
Access Full Report @ https://www.databridgemarketresearch.com/de/reports/europe-medicinal-chemistry-for-drug-discovery-market
Data Bridge Market Research analyses that the Europe Medicinal Chemistry for Drug Discovery Market value, which was USD 1,392.96 million in 2021, is expected to reach the value of 3,890.66 million by 2029, at a CAGR of 13.7% during the forecast period 2022-2029. The expansion of healthcare access in developing countries is a driver for the medicinal chemistry for drug discovery market as it creates a growing demand for affordable and innovative medications, thus fueling market expansion and global pharmaceutical development.
Key Findings of the Study
Aging population is expected to drive the market's growth rate
The aging population is a significant driver of the medicinal chemistry for drug discovery market. With a growing demographic of elderly individuals, there is an increased need for pharmaceutical solutions to address age-related health issues, chronic diseases, and conditions that affect the elderly. This demand fuels research and development efforts to create medications tailored to the needs of an aging population, making the market an essential player in healthcare advancements for the elderly.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014-2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Process (Target Selection, Target Validation, Hit-To-Lead Identification, Lead Optimization, and Candidate Validation), Design (Fragment-Based Variation, Structure-Based Drug Design, Diversity Oriented Synthesis, Chemogenomics, Natural Products, and Others), Drug Type (Small Molecules and Biologics), Therapeutic Area (Oncology, Neurology, Infectious and Immune System Diseases, Cardiovascular Diseases, Digestive System Diseases and Others), End User (Contract Research Organization, Pharmaceuticals and Biotechnology Companies, Academic and Research Institutes and Others)
|
|
Countries Covered
|
Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.
|
|
Market Players Covered
|
Eurofins Scientific (Luxembourg), Covance Inc. (U.S.), WuXi AppTec (China), Charles River (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Pfizer, Inc. (U.S.), Certara, USA (U.S.), Malvern Panalytical Ltd (United Kingdom), GenScript Biotech Corporation (China), Aurigene Pharmaceutical Services Ltd. (India), Selvita (Poland)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The Europe medicinal chemistry for drug discovery market is segmented on the basis of process, design, drug type, therapeutic area, and end user.
- On the basis of process, the Europe medicinal chemistry for drug discovery market is segmented into target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation.
- On the basis of design, the Europe medicinal chemistry for drug discovery market is segmented into fragment-based variation, structure-based drug design, diversity oriented synthesis, chemogenomics, natural products, and others.
- On the basis of drug type, the Europe medicinal chemistry for drug discovery market is segmented into small molecules and biologics.
- On the basis of therapeutic area, the Europe medicinal chemistry for drug discovery market is segmented into oncology, infectious and immune system disease, neurology, cardiovascular disease, digestive system disease, and others.
- On the basis of end user, the Europe medicinal chemistry for drug discovery market is segmented into contract research organization, academic and research institutes, pharmaceutical and biotechnology companies, and others.
Major Players
Data Bridge Market Research recognizes the following companies as the Europe medicinal chemistry for drug discovery market players in Europe medicinal chemistry for drug discovery market are Eurofins Scientific (Luxembourg), Covance Inc. (U.S.), WuXi AppTec (China), Charles River (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Pfizer, Inc. (U.S.), Certara, USA (U.S.).
Market Developments
- In May 2021, Charles River entered a firm agreement to acquire Vigene Biosciences, Inc., a leading U.S.-based contract development and manufacturing organization (CDMO) specializing in gene therapy. Vigene Biosciences is known for its viral vector-based gene delivery solutions, which augment drug discovery efforts. This strategic move has bolstered Charles River's presence and capabilities in the medicinal chemistry for drug discovery market.
- In August 2020, Malvern Analytical introduced Amplify Analytics, a groundbreaking platform enabling pharmaceutical firms to swiftly pinpoint drug candidates with optimal bioavailability, thereby expediting the drug development cycle. This innovative solution has significantly enhanced Malvern Analytical's position in the medicinal chemistry for drug discovery market by offering pharmaceutical companies a competitive edge in selecting promising compounds, reducing research timelines, and ultimately driving business growth in the field of drug discovery.
Regional Analysis
Geographically, the countries covered in the Europe medicinal chemistry for drug discovery market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.
As per Data Bridge Market Research analysis:
Germany is the dominant region in the Europe medicinal chemistry for drug discovery market during the forecast period 2022-2029
Germany dominates the Europe medicinal chemistry for drug discovery market, with the target selection segment taking the lead. This is primarily driven by a surge in collaborative efforts between researchers and pharmaceutical companies in the country. Such partnerships foster innovative drug development, creating a dynamic ecosystem that propels Germany to a prominent position in the medicinal chemistry field and further advances the nation's pharmaceutical industry.
U.K. is expected to dominate the Europe medicinal chemistry for drug discovery market in the forecast period 2022-2029
The U.K. is poised for growth in the European medicinal chemistry for drug discovery market, driven by substantial technological advancements in drug development. These innovations enhance the drug discovery process, making it more efficient and targeted. This growth trend positions the UK as a key player in the pharmaceutical industry within Europe, with a focus on cutting-edge research and development for novel therapies and medications.
For more detailed information about the Europe medicinal chemistry for drug discovery market report, click here – https://www.databridgemarketresearch.com/de/reports/europe-medicinal-chemistry-for-drug-discovery-market
